.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, patients along with metastatic intestinal lumps who got biomarker-matched treatments based on spreading lump DNA profiling revealed a better scientific benefit than those acquiring unparalleled treatment.